Please call 800-398-9157 for information on this study

Men and women of age 18 years or older inclusive

Recipient of a renal allograft for at least ≥ 2 months

EBV positive

Unable to tolerate a suitable immunosuppression regimen to prevent acute allograft rejection, due to:

Extra-renal toxicity related to CNIs and/or m-TOR inhibitors that is refractory to medical management (eg, uncontrolled seizures)

Contraindication to CNIs and/or m-TOR inhibitors

OR

At imminent risk of losing allograft kidney due to nephrotoxicity

Renal failure: ≥ Stage 4 on KDOQI Scale (GFR 15 - 29 cc/min)

And no other renal replacement therapy

Subjects must be receiving the maintenance immunosuppressants MMF, MPA, or AZA

A Belatacept Compassionate Use Study for Patients With a Kidney Transplant